Trump administration delays rule that could curb imported prescription drugs

The Trump administration announced a 90‑day postponement of a federal rule that would have limited Americans’ ability to purchase prescription medicines from licensed pharmacies abroad.

The rule was intended to crack down on illegal shipments, especially opioids, by eliminating the de minimis exemption that allowed low‑value shipments under $800 to clear customs with minimal paperwork.

Patient advocacy groups and many members of Congress have criticized the rule, warning it could sharply reduce the flow of affordable drugs from Canada and other countries, prompting the administration to reconsider.

The delay pushes the original effective date from Oct. 22 to early 2027, giving stakeholders more time to evaluate the policy and potentially adjust the approach to balancing drug safety with access.